Cellectis to present at the British Society for Gene Therapy Annual Conference
Paris, March 23, 2010 – Cellectis (Alternext: ALCLS), the French Genome
engineering specialist, announces today that Frédéric Pâques, PhD, Chief
Scientific Officer, will present Cellectis’ technologies and their application in
genome surgery at the 7th British Society for gene Therapy Annual Conference to
be held at Royal Holloway, University of London, on March 29-31, 2010.
Targeted approaches have emerged today as an alternative to current random
insertion strategies for gene therapy. Such approaches include the targeted
insertion of therapeutic transgenes into chosen loci, the precise editing of
deleterious mutation (gene correction), as well as various gene deletion and
knock-out strategies. A variety of different tools have been envisioned, including
integrases, recombinases, transposases and endonucleases. Meganucleases, the
most specific endonucleases, represent ideal tools for precise Genome editing or
genome surgery.
Dr Pâques will discuss the use of “Meganucleases for Genome surgery” on March
30, 2010, at 9.20AM, during an oral session on Genome Engineering.
